Context: New strategies and biomarkers are needed in the early detection of b-cell damage in the progress of type 1 diabetes mellitus (T1DM).
on elevation of blood glucose and reduction in plasma insulin and/or C-peptide. These parameters are good for identifying b-cell damage, but only useful in established type 1 diabetes mellitus (T1DM). Autoantibodies are considered markers of the autoimmune process early in the disease, but they often do not reflect the degree of b-cell damage (2) . Unmethylated insulin DNA is regarded as a potential parameter for early b-cell damage, but its use is limited by the relative low concentration in plasma, and the amount of unmethylated DNA release might be affected by the mechanisms causing b-cell death (3) . So, there is clearly a need for new methods to identify patients with early T1DM or individuals on their way to developing T1DM.
MicroRNAs (miRNAs) are a class of small noncoding RNAs of approximately 22 nucleotides in length that posttranscriptionally regulate gene expression in various biological processes (4) . Tissue-specific miRNAs already serve as noninvasive markers in the study of cancers, immunological diseases, cardiovascular diseases, and type 2 diabetes mellitus (5) (6) (7) (8) (9) . miRNAs can be detected in serum, plasma, urine, and tears by polymerase chain reaction (PCR) with high specificity, which makes miRNAs ideal biomarker candidates for different diseases (10) . miRNAs play an important role in the regulation of b-cell function, including proliferation and apoptosis (11) (12) (13) . However, it remains unknown if circulating miRNAs can be used as a biomarker for early diagnosis of b-cell damage in T1DM.
In the current study, we established a miRNA-based model with a high specificity and sensitivity in the evaluation of b-cell damage in vivo and vitro.
Subjects and Methods

Clinical subjects and research design
Seventy-nine patients with recent-onset T1DM were recruited in the Guangdong T1DM Translational Medicine Study Program between August 2011 and June 2014 (14) . The diagnostic criteria for T1DM are: (1) insulin-dependent during long-term follow-up, (2) positive for at least one of following autoantibodies: antibodies against the 65-kDa isoform of glutamate decarboxylase, insulinoma antigen 2, or zinc transporter 8, as determined with a radiobinding assay confirmed by the Islet Autoantibody Standardization Program, (3) disease duration ,1 year, and (4) fasting and stimulated C-peptide levels are ,0.6 ng/mL and 0.9 ng/mL, respectively (Supplemental Methods). Age-and sex-matched healthy individuals who are negative for the three diabetes-associated autoantibodies and a family history of diabetes were recruited from the physical examination center of the Third Affiliated Hospital of Sun Yatsen University. Individuals with any febrile illness, accompanied diabetic complications, or other diseases were excluded from the study. The study was approved by the Ethics Committee of the Third Affiliated Hospital of Sun Yat-sen University. Written informed consent was obtained from adult participants or from the parents/guardians of individuals younger than age 18 years.
miRNA-based screening model for T1DM
Discovery phase
The human miRNA microarray, including 2006 mature miRNA sequences, was initially used to establish the serum miRNA profiles of patients with T1DM and matched healthy controls with six individuals in each group (Fig. 1) . The MannWhitney U test was performed to identify differentially expressed miRNAs. A twofold difference in miRNA expression (P , 0.05) was used in identification of significant difference in the data analysis. Six miRNAs (miR-642a-3p, miR-320c, miR-1225-5p, let-7b-5p, miR-26b-5p, and miR-144-3p) were selected as candidate miRNAs. The selection criteria were as follows: (1) to maximize differences, the miRNAs with at least a 2.5-fold change in levels between the T1DM and control groups were chosen (2) for high expression and better detection, the miRNAs with intensive signal (mean flag value .3 in either group) in the microarrays were selected, and (3) for strong association with T1DM, miRNAs should have at least three 
Training phase
The six candidate miRNAs were verified in a training cohort, 40 patients with recent-onset T1DM and 56 healthy controls, with their relative expression levels determined by quantitative reverse transcription (qRT)-PCR. Next, a miRNA-based model was developed using logistic regression analysis based on the training dataset. Receiver-operating characteristic (ROC) curves and leave-one-out cross-validation was used to evaluate the diagnostic performance of the model.
Validation phase
The performance of the miRNA-based model was validated by differentiating T1DM cases from healthy controls in another independent validation cohort including 33 patients with recent-onset T1DM and 29 healthy controls.
Functional phase
The association of b-cell damage with the identified miRNAs in the model was confirmed in streptozotocin (STZ)-treated mice and INS-1 cell as well as in a nonobese diabetic (NOD) mice model of T1DM.
Microarray and qRT-PCR
We used the Agilent human miRNA microarray V19.0 (Agilent Technologies, Santa Clara, CA) in our study. The microarray data have been deposited in the NCBI Gene Expression Omnibus (GSE94649, http://www.ncbi.nlm.nih.gov/ geo). The qRT-PCR was performed using TaqMan primers according to the manufacturer protocol (Applied Biosystems, Foster City, CA) (Supplemental Methods). U6 small nuclear RNA was chosen as a stable endogenous control (16) . The relative expression levels of the miRNAs were calculated using the 2 2DCt method, in which DCt = Ct (target) -Ct (reference) (17) . Animals C57BL/6 male mice (n = 8) and female NOD/ShiLtJ (NOD) mice (n = 12) were purchased from Beijing HFK Bioscience CO., Ltd. (Beijing, China). Mice were kept under specific pathogenfree conditions in a 12-hour dark, 12-hour light cycle with free access to food and water. C57BL/6 male mice (n = 4) were treated by intraperitoneal injection of multiple doses (50 mg/kg) of STZ (Sigma-Aldrich Inc., St Louis, MO) for 5 consecutive days. The control mice (n = 4) were injected with the same volume of vehicle. Mice with fasting blood glucose of 11.1 mmol/L or more for 2 consecutive days were considered diabetic. All procedures with animals complied with the Guide for the Care and Use of Laboratory Animals and were approved by the animal care and use committee of Sun Yat-sen University.
Flow cytometry analysis
INS-1 cells without mycoplasma contamination were obtained from Key Laboratory of Human Functional Genomics of Jiangsu Province (Nanjing, Jiangsu, China). INS-1 cells were cultured in six-well plates and treated with STZ for 24 hours to induce apoptosis. Then, the cells were collected after digestion with 0.25% trypsin and incubated with 20 mL of binding buffer, 5 mL of Annexin V-FITC, and 5 mL of propidium iodide. After incubation at room temperature in the dark for 15 minutes, cells were analyzed with a flow cytometry for apoptosis. The results were calculated using CellQuest TM Pro software (BD Biosciences, Mississauga, ON, Canada) and expressed as the percentage of apoptotic cells among the total cells.
TUNEL staining assay
INS-1 cells were cultured on a cover glass in 24-well plates and treated with STZ for 24 hours to induce apoptosis. Then, the apoptotic cells were stained in a terminal deoxynucleotidyl transferase mediated nick-end labeling (TUNEL) assay according to the instruction of the kit manufacturer (In Situ Cell Death Detection Kit; Roche, Basel, Switzerland). Apoptotic cells were stained by green fluorescence, and all cells were marked with blue fluorescence using Hoechst. The apoptotic ratio was calculated as TUNEL-positive cells divided by total cell number. The number of cells was counted in five random fields from three different slides at 3400 magnification. The average of TUNEL-positive cells was expressed in percentage in these fields.
Statistical analysis
Data are presented as mean 6 standard error or median (interquartile range) for continuous variables and as n (%) for categorical variables. Comparisons between two groups were analyzed using the Student t, Mann-Whitney U, or x 2 test.
Development and evaluation of the miRNA-based model
The candidate miRNAs showing significant differential expression between T1DM cases and controls were introduced into a binary logistic regression model controlling for age, sex, and body mass index (BMI), and step-wise backward selection was performed to determinate the best model for discriminating patients with T1DM from healthy individuals. ROC curves were constructed to evaluate the discriminatory performance of each miRNA and the model for differentiating T1DM cases from healthy controls according to the area under the ROC curve (AUC) value.
Simulation studies were performed to test the magnitude of the bias introduced by model selection. Leave-one-out crossvalidation was used to validate the logistic diagnostic model based on the training dataset (Supplemental Methods) SPSS, version 20.0, software (SPSS Inc., Chicago, IL) and R, version 3.0.2, software (R Foundation for Statistical Computing, Vienna, Austria) (18) were used for statistical analysis. Statistical significance was defined as a two-tailed P , 0.05.
Results
Identification of candidate miRNAs
To identify the serum miRNAs that could be used in diagnosis of T1DM, we determined miRNA profiles in the serum of six patients with recent-onset T1DM and six healthy individuals using a microarray (see clinical characteristics of subjects in Supplemental Table 1) . A difference was observed in 27 miRNAs between the patients and controls (fold change $2, P , 0.05; Supplemental Table 2 ), 17 of which increased and 10 of which decreased in patients with T1DM. According to the further selection criteria in this study (see the Clinical subjects and research design section of this article), six miRNAs (miR-642a-3p, miR-320c, miR-1225-5p, let7b-5p, miR-26b-5p, and miR-144-3p) were selected as candidates for the next round of biomarker study. Predicted target genes are shown in Supplemental Table 3 .
Development of a miRNA-based model
To test the value of candidate miRNAs, we examined them by qRT-PCR in the training cohort, which included 40 patients with recent-onset T1DM and 56 healthy controls. The age and sex were well matched in the two groups of this cohort (see clinical characteristics of subjects in Table 1 ). The levels of all the six miRNAs were increased in patients with T1DM (Fig. 2, all P , 0.05) ; three miRNAs (miR-642a-3p, miR-320c, and miR-1225-5p) were consistent with the results of microarray study.
To establish a diagnostic model that could be used efficiently for identification of patients with T1DM, a logistic regression analysis was applied to the training dataset to estimate the accuracy rate in the diagnosis of T1DM. Specifically, the six candidate miRNAs were initially introduced into the model and adjusted for potential confounders (age, sex, and BMI).
Step-wise backward selection was performed to determine the best model as following: logit (P = T1DM) = 0.613 + 0.174 3 miR-320c -2.199 3 miR-1225-5p + 0.09 3 age -0.213 3 BMI, which saved the independent significant items for last to optimize the combination and avoid overfitting (Supplemental Table 4 ). The model was tested using a likelihood test and was found to be significant (x 2 = 37.75 and P , 0.001).
The diagnostic performance of the model was evaluated with ROC analysis. As shown in Fig. 3A , the AUC value of the model was 0.817 (95% confidence interval, 0.731 to 0.903; P , 0.001), which was higher than that of each individual miRNA (Supplemental Table 5 ). The optimal cutoff point was defined when the Youden index reached the maximum. The corresponding sensitivity, specificity, positive predictive value, and negative predictive value were 55.0%, 92.9%, 84.6%, and 74.3%, respectively.
A simulation study was performed to evaluate the miRNA-based model for overfitting. A series of empirical P values for the model's AUC was obtained; the highest simulated AUC value with P , 0.001 was 0.801. In addition, leave-one-out cross-validation was used to evaluate the discriminatory performance further for T1DM in the training dataset. The resulting error rate was 18.3%, suggesting that the model had a good stability and reliability.
Validation of the miRNA-based model in another independent dataset
The model was validated in another cohort including 33 patients with recent-onset T1DM and 29 healthy controls ( Table 1 ). The levels of miR-320c and miR-1225-5p in this validation cohort are reported in Supplemental Fig. 2 . The parameters of the model were applied to the validation dataset to evaluate the probability of being diagnosed with T1DM. The predictive probability was used to construct the ROC curve. As shown in Fig. 3B , the AUC value of the model was 0.804 (95% confidence interval, 0.688 to 0.921; P , 0.001). When the Youden index reached the maximum, miR-1225-5p and miR-320c were increased in both STZ-treated mice and INS-1 cells To investigate the relationship of the candidate miRNAs and b-cell damage, we used a mouse model of insulin deficiency to mimic the situation in T1DM, in which C57BL/6 mice were treated with STZ daily for 5 days to induce b-cell damage. The model was successfully established as indicated by the elevation of blood glucose (22.40 6 1.91 mM vs 7.63 6 0.46 mM at day 7) (Fig. 4A) . Serum miR-1225-5p and miR-320c were increased in the mice at 1.83-and 1.73-fold, respectively, on day 7 after STZ administration (Fig. 4B) .
The relationship between miR-1225-5p and miR-320c and b-cell death was investigated in the cell culture system. Apoptosis of INS-1 cells was induced with STZ treatment; the result was confirmed with Annexin V/PI staining and TUNEL assays. Apoptotic rate of INS-1 cells was significantly increased by the STZ treatment in the Annexin V/PI assay (Fig. 4C) . The percentage of apoptotic cells was increased by 200% in the TUNEL assay (26.0% vs 8.2%) (Fig. 4D) . miR-1225-5p was increased by 47.3-fold in apoptotic INS-1 cells. The increase was Figure 2 . Relative levels of six candidate serum miRNAs in the training dataset, which included 40 T1DM cases and 56 healthy controls. Values of miRNA level were log-transformed for analysis. *P , 0.05; **P , 0.01; ***P , 0.001. also detected in the culture medium of apoptotic cells at 1.8-fold. miR-320c exhibited a 3.1-fold increases in the cell lysate and 4.1-fold increase in the culture medium (Fig. 4E) .
miR-1225-5p and miR-320c were increased in serum before glucose elevation in NOD mice
The value of serum miR-1225-5p and miR-320c was examined for early diagnosis of T1DM in NOD mice. Peri-insulitis usually occurs at 6 to 8 weeks of age in NOD mice, which leads to initial damage in b cells, providing an excellent model for testing our diagnostic parameters. The onset of diabetes occurs at approximately 13 to 14 weeks of age in NOD mice. The serum levels of miR-1225-5p and miR-320c were examined at the ages of 4, 8, and 14 weeks in NOD mice. It was noteworthy that a significant increase in expression of both miR-1225-5p and miR-320c was observed at the age of 8 weeks before the elevation of blood glucose (Fig. 5A and 5B). Interestingly, the mice without peri-insulitis did not exhibit an alteration in the miRNAs at the age of 8 weeks (data not shown). According to the five infiltration categories, the NOD mice remained free of insulitis at the age of 4 weeks, peri-and/or mild insulitis were found in majority of islets at the age of 8 weeks, and severe insulitis was found in 14-week-old mice (Fig. 5C and 5D ).
Discussion
We established a miRNA-based model (including miR-1225-5p, miR-320c, age, and BMI) with a good discriminatory performance between T1DM and healthy controls. Two miRNAs (miR-1225-5p and miR-320c) exhibited the strong association with b-cell damage as indicated by data from STZ-treated INS-1 cells and mice. The two miRNAs also exhibited a good performance in the early detection of b-cell damage in NOD mice. These observations consistently suggest that the serum miRNAs (miR-1225-5p and miR-320c) are potential biomarkers in the early diagnosis of T1DM.
Circulating miRNAs are being investigated as potential biomarkers for various diseases providing noninvasive, rapid, sensitive, specific diagnostic and prognostic measures. Although several circulating miRNAs have been reported in T1DM (19) (20) (21) , their value in early diagnosis is limited. Several studies were restricted to analysis of expression of only one or a few miRNAs, with lack of validation of diagnostic performance. Most important, the studies did not provide the functional data on the miRNAs identified. In our study, a high-throughput microarray was used for initial global miRNA screening and our miRNA-based model was systematically tested by multiple approaches including simulation study, leaveone-out cross-validation, and another independent dataset to guarantee the reliability of model selection and parameter estimation. It was also demonstrated that combinations of miRNAs with risk factors would be superior to individual miRNAs in the discriminatory performance.
Notably, STZ treatment, which selectively destroys b cells, resulted in increases of circulating levels of miR320c and miR-1225-5p in mice. Also, massive b-cell loss elicited by administration of STZ caused a dramatic rise of the two miRNAs in cells and medium. The NOD mice model did exhibit elevations in miR-320c and miR-1225-5p during the weeks with peri-insulitis before development of manifested hyperglycemia. In contrast, these two markers did not change in the NOD mice without insulitis at 4 and 8 weeks. These data indicated that serum miR-1225-5p and miR-320c showed a clear correlation to b-cell damage in the progress of diabetes in NOD mice.
Strikingly, miR-1225-5p increased by 47.3-fold in apoptotic INS-1 cells but 1.8-fold in the culture medium. Changes in concentrations of miR-320c and miR-1225-5p could occur in b cells in T1DM as a consequence of active and selective transportation rather than a passive consequence of cell lysis. Previous studies have indicated that miR-320c and miR-1225-5p can be wrapped into exosomes, which protect miRNAs from degradation by RNAse and serve as vehicles for miRNA secretion into extracellular space and body fluids (22) . Therefore, we speculate that the increased circulating miRNAs could be released from dying b cells via exosomes or other vehicles, although we cannot specifically exclude the possibility that other cells such as a cells also can release miRNAs after STZ treatment.
This article identified miR-320c and miR-1225-5p in the T1DM serum for evaluation of b-cell activity. Bioinformatics analysis suggests that miR-320c may regulate several candidate genes for T1DM, including STAT4, SH2B3, RASGRP1, and CCR7 (23, 24) . miR-320c has also been studied for its role in the signaling pathway of transforming growth factor-b, cell cycle, and endocytosis (25, 26) . Blume et al. demonstrated that miR-320c mediates p53 effects in the regulation of cell cycle and apoptosis (27) . With respect to miR-1225-5p, previous Results are presented as the mean score of n = 5 mice in each group; for each pancreas, an average insulitis score was calculated by adding the score of each islet and then dividing by the total number of islets counted. N.S., nonsignificant; w, week. *P , 0.05; **P , 0.01; ***P , 0.001. studies have suggested its involvement in the Wnt signaling pathway, which is related to the process of apoptosis and cell-cycle regulation (28, 29) . Dysregulated Wnt signaling may be an important contributor to b-cell death in T1DM pathogenesis (30) . These studies suggest that miR-320c and miR-1225-5p may play important roles in apoptosis.
Several confounding factors should be taken into account when interpreting the results of miRNA expression profiles. Numerous studies have addressed age-related modifications in circulating miRNA levels (31, 32) . It has also been suggested that BMI can influence expression levels of circulating miRNAs. Ortega et al. found that circulating miRNAs were deregulated in severe obesity, and that subsequent weight loss could induce changes in the expression profile (33) . Our study provided a reasonable adjustment for age and BMI in the model.
There are some limitations of this study that should be acknowledged. First, there was no glucose threshold used to define poor b-cell secretory capacity in the mixed-meal tests. Second, this is a miRNA-based model in a Chinese population with the lowest incidence rate in the world. Further validation studies are needed in a larger sample size, and, ideally, among patients of different ethnic origin. Third, although we established this model for discriminating patients with T1DM from controls, and found the potential value for early detection of b-cell damage in NOD mice, the cohort with high-risk T1DM development (such as The Environmental Determinants of Diabetes in the Young cohort) (34) is needed to determine the value of the model in early clinical diagnosis of T1DM.
Conclusion
In conclusion, we identified two miRNA biomarkers (miR-1225-5p and miR-320c) that were found to be related to b-cell damage. We also established the miRNAbased model and validated its good performance in diagnosis of T1DM. These two biomarkers' potential value in the early diagnosis of diabetes development was preliminarily confirmed in NOD mice. Further clinical studies are needed to evaluate these findings.
